Literature DB >> 23707018

The impact of Dupuytren disease on patient activity and quality of life.

J Wilburn1, S P McKenna, D Perry-Hinsley, A Bayat.   

Abstract

PURPOSE: To explore the impact of Dupuytren disease (DD) from the patients' perspective.
METHODS: Audio-recorded interviews were conducted for patients with Dupuytren disease (DD) attending outpatient clinics. The interviews were transcribed and subjected to content analysis. This analysis highlighted key impact areas and common themes in individuals' personal experiences. These were then allocated to categories specified by the World Health Organization International Classification of Functioning, Disability, and Health (impairments and activity limitations) and the needs-based model of quality of life (QoL).
RESULTS: Qualitative unstructured interviews were conducted with 34 patients (74% men; age, 41-80 y; mean [SD], 64 [13] y). The sample had a wide range of severity and duration of DD (range, 0.5-40; mean [SD], 13 [10] y). Nine hundred fifty-three statements relating to the impact of DD were identified from the interview transcripts. These statements fell into 2 major categories of impact: activity limitations (10 themes including problems with dressing, gripping, and personal care) and QoL (6 need categories: physiological, safety and security, social, affection, esteem, and cognitive needs).
CONCLUSIONS: Findings from the interviews suggest that DD affects both performance of activities and QoL. To determine accurately the effectiveness of DD interventions from the patients' perspective, it is important to determine their impacts on both activity limitations and QoL. We intend to develop valid, reproducible, and responsive DD-specific scales for this purpose. CLINICAL RELEVANCE: The study identifies key issues specific to DD that influence patients' functioning and QoL. The information reported will form the basis of DD-specific patient-reported outcomes measures for use in clinical practice and evaluations of interventions.
Copyright © 2013 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23707018     DOI: 10.1016/j.jhsa.2013.03.036

Source DB:  PubMed          Journal:  J Hand Surg Am        ISSN: 0363-5023            Impact factor:   2.230


  18 in total

1.  Clinical outcomes following collagenase injections compared to fasciectomy in the treatment of Dupuytren's contracture.

Authors:  Raghuveer C Muppavarapu; Michael J Waters; Matthew I Leibman; Mark R Belsky; David E Ruchelsman
Journal:  Hand (N Y)       Date:  2015-06

2.  MRI in flexor tendon rupture after collagenase injection.

Authors:  Shruti Khurana; Vibhor Wadhwa; Avneesh Chhabra; Bardia Amirlak
Journal:  Skeletal Radiol       Date:  2016-11-25       Impact factor: 2.199

Review 3.  Collagenase clostridium histolyticum in Dupuytren's contracture: a systematic review.

Authors:  Francesco Smeraglia; Angelo Del Buono; Nicola Maffulli
Journal:  Br Med Bull       Date:  2016-05-05       Impact factor: 4.291

4.  Psychometric evaluation of the Disabilities of the Arm, Shoulder and Hand (DASH) with Dupuytren's contracture: validity evidence using Rasch modeling.

Authors:  Nancy J Forget; Christina Jerosch-Herold; Lee Shepstone; Johanne Higgins
Journal:  BMC Musculoskelet Disord       Date:  2014-10-30       Impact factor: 2.362

5.  Development of an instrument evaluating the impact of surgeon-patient relationship in patients on sick leave.

Authors:  Thierry Dubert; Cedric Girault; Alexandre Kilink; Marc Rozenblat; Yves Lebellec; Anne-Lise Vataire; Myriam Vilasco; Gregory Katz
Journal:  J Mark Access Health Policy       Date:  2017-08-11

6.  Collagenase Clostridium histolyticum Injection Therapy Improves Health-related Quality of Life in Patients with Dupuytren's Disease.

Authors:  Takuro Kuboi; Tsuyoshi Tajika; Fumitaka Endo; Wataru Goto; Ichiro Nakajima; Satoshi Hasegawa; Daisuke Nakajima; Takafumi Hasokawa; Hirotaka Chikuda
Journal:  Prog Rehabil Med       Date:  2021-05-26

7.  Self-perceived health status following aneurysmal subarachnoid haemorrhage: a cohort study.

Authors:  Audrey C Quinn; Deepti Bhargava; Yahia Z Al-Tamimi; Matthew J Clark; Stuart A Ross; Alan Tennant
Journal:  BMJ Open       Date:  2014-04-03       Impact factor: 2.692

8.  Surgical treatment of Dupuytren's disease - outcome and health economy in relation to smoking and diabetes.

Authors:  David Eckerdal; Axel Nivestam; Lars B Dahlin
Journal:  BMC Musculoskelet Disord       Date:  2014-04-02       Impact factor: 2.362

Review 9.  What do we know about managing Dupuytren's disease cost-effectively?

Authors:  Melina Dritsaki; Oliver Rivero-Arias; Alastair Gray; Catherine Ball; Jagdeep Nanchahal
Journal:  BMC Musculoskelet Disord       Date:  2018-01-25       Impact factor: 2.362

10.  A Genome-wide Association Study of Dupuytren Disease Reveals 17 Additional Variants Implicated in Fibrosis.

Authors:  Michael Ng; Dipti Thakkar; Lorraine Southam; Paul Werker; Roel Ophoff; Kerstin Becker; Michael Nothnagel; Andre Franke; Peter Nürnberg; Ana Isabel Espirito-Santo; David Izadi; Hans Christian Hennies; Jagdeep Nanchahal; Eleftheria Zeggini; Dominic Furniss
Journal:  Am J Hum Genet       Date:  2017-09-07       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.